In agreement with this, promising preclinical data prompted the launch of three phase I/II clinical trials aimed at assessing the safety and efficacy of ROBO-1-directed CAR-NK cell therapy in PDAC and other solid tumours depending on ROBO-1 expression on cancer cells (NCT03941457, NCT03940820 and NCT03931720). Here, ROBO1 is linked to cancer.